Intas B2B announces successful development of complex Metoprolol Succinate Slow Release Tablets formulation for Europe. With current sales of $238M the product is used to treat high blood pressure.
Intas B2B will now start submitting generic DCP applications in different EU countries.
Please reach out to our BD&L team for licensing and supply partnerships.
